AbbVie Gross Profit 2010-2018 | ABBV

AbbVie annual/quarterly gross profit history and growth rate from 2010 to 2018. Gross profit can be defined as the profit a company makes after deducting the variable costs directly associated with making and selling its products or providing its services.
  • AbbVie gross profit for the quarter ending December 31, 2018 was $6.283B, a 15.12% increase year-over-year.
  • AbbVie gross profit for the twelve months ending December 31, 2018 was $25.035B, a 18.23% increase year-over-year.
  • AbbVie annual gross profit for 2018 was $25.035B, a 18.23% increase from 2017.
  • AbbVie annual gross profit for 2017 was $21.174B, a 6.91% increase from 2016.
  • AbbVie annual gross profit for 2016 was $19.806B, a 7.88% increase from 2015.
AbbVie Annual Gross Profit
(Millions of US $)
2018 $25,035
2017 $21,174
2016 $19,806
2015 $18,359
2014 $15,534
2013 $14,209
2012 $13,872
2011 $12,805
2010 $11,345
2009 $10,158
AbbVie Quarterly Gross Profit
(Millions of US $)
Q4 2018 $6,283
Q3 2018 $6,401
Q2 2018 $6,344
Q1 2018 $6,007
Q4 2017 $5,458
Q3 2017 $5,379
Q2 2017 $5,415
Q1 2017 $4,922
Q4 2016 $5,242
Q3 2016 $4,928
Q2 2016 $5,047
Q1 2016 $4,589
Q4 2015 $4,925
Q3 2015 $4,777
Q2 2015 $4,559
Q1 2015 $4,098
Q4 2014 $4,333
Q3 2014 $3,925
Q2 2014 $3,813
Q1 2014 $3,463
Q4 2013 $3,829
Q3 2013 $3,566
Q2 2013 $3,638
Q1 2013 $3,176
Q4 2012 $3,941
Q3 2012 $3,494
Q2 2012 $3,420
Q1 2012 $3,017
Q4 2011 $1,432
Q3 2011 $4,409
Q2 2011 $4,274
Q1 2011 $2,689
Q4 2010 $0
Q4 2009 $0
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $115.027B $32.753B
AbbVie is a global, research-based biopharmaceutical company. AbbVie combines the focus and passion of a leading-edge biotech with the expertise and structure of a long-established pharmaceutical leader. The company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. AbbVie aims to help patients' live healthier lives and collaborate on sustainable healthcare solutions.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $371.636B 16.85
Pfizer (PFE) United States $237.400B 13.29
Merck (MRK) United States $199.302B 17.03
Novartis AG (NVS) Switzerland $178.563B 15.19
Eli Lilly (LLY) United States $120.673B 20.95
Novo Nordisk (NVO) Denmark $118.536B 19.17
Sanofi (SNY) France $103.057B 12.72
GlaxoSmithKline (GSK) United Kingdom $99.174B 13.02
AstraZeneca (AZN) United Kingdom $98.200B 11.20
Bristol-Myers Squibb (BMY) United States $74.835B 11.51